Transplant tumor registry: donor related malignancies

Kauffman, H. Myron; McBride, Maureen; Cherikh, Wida S.; Spain, Pamela; Marks, William H.; Roza, Allan M.

doi:10.1097/00007890-200208150-00011

Cited by 218 publications

(142 citation statements)

References 17 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…The first reported case of cancer transmission from a living organ donor was a breast cancer transmitted from a donor wife to recipient husband, but lung, lymphoma, and renal cell cancer have also been recorded (Kauffman et al 2002). The young age of most living organ donors provides a degree of protection against cancer transmission because of the strong ageassociated risk of cancer; however, many of the common cancers such as breast, colon, prostate, cervix, and in Australia also melanoma, are sufficiently prevalent that one case might be expected to be transmitted unknowingly every 5000 living donations.…”

Section: Living Donor Assessment For Cancer Riskmentioning

confidence: 99%

Cancer in the Transplant Recipient

Chapman

Webster

Wong

2013

Cold Spring Harbor Perspectives in Medicine

239

187

View full text Add to dashboard Cite

Malignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ transplant programs. Death from cardiovascular disease and infection are both decreasing in frequency from a combination of screening, prophylaxis, aggressive risk factor management, and interventional therapies. Cancer, on the other hand, is poorly and expensively screened for; risk factors are mostly elusive and/or hard to impact on except for the use of immunosuppression itself; and finally therapeutic approaches to the transplant recipient with cancer are often nihilistic. This article provides a review of each of the issues as they come to affect transplantation: cancer before wait-listing, cancer transmission from the donor, cancer after transplantation, outcomes of transplant recipients after a diagnosis of cancer, and the role of screening and therapy in reducing the impact of cancer in transplant recipients.

show abstract

Section: Living Donor Assessment For Cancer Riskmentioning

confidence: 99%

Cancer in the Transplant Recipient

Chapman

Webster

Wong

2013

Cold Spring Harbor Perspectives in Medicine

239

187

View full text Add to dashboard Cite

show abstract

“…Thus far, there have been 17 documented cases of donor-transmitted malignancies to liver transplant recipients (Table 2). 48,49 Based on these data, cancer histologies with prohibitively high transmission risk include melanoma and choriocarcinoma. The cancer-free interval must also be considered on evaluation of donors with a history of malignancy.…”

Section: Donors With Malignanciesmentioning

confidence: 99%

“…However, tumors that may possess the potential of unpredictable recurrence include breast, colon, lung, melanoma, and renal cell carcinoma. 49 Donors with histories of primary central nervous system (CNS) tumors have also been evaluated. 48 Between January 1992 and December 1999, 397 of 42,340 cadaver donors had a history of CNS tumors.…”

Section: Donors With Malignanciesmentioning

confidence: 99%

The utility of marginal donors in liver transplantation

Busuttil¹

2003

Liver Transplantation

629

508

View full text Add to dashboard Cite

The shortage of organs has led centers to expand their criteria for the acceptance of marginal donors. The combination of multiple marginal factors seems to be additive on graft injury. In this review, the utility of various marginal donors in patients requiring liver transplantation will be described, including older donors, steatotic livers, non-heart-beating donors, donors with viral hepatitis, and donors with malignancies. The pathophysiology of the marginal donor will be discussed, along with strategies for minimizing the ischemia reperfusion injury experienced by these organs. Finally, new strategies for improving the function of the marginal/expanded donor liver will be reviewed. (Liver Transpl 2003;9:651-663.)

show abstract

“…Although there have been instances in which cessation of immunosuppression has contributed to the cure of a donor-derived neoplasm, including broncho- genic carcinoma transferred by kidney transplantation, 3 progression of malignancy despite restitution of the immune system also has been well documented. 4,5 Therefore, in today's climate of critical organ shortage, for a potential donor with known malignancy, either past or current, the estimated risk for cancer transmission tempers the evaluation, consideration, and acceptance of his or her organs by the individual transplant physicians and candidates. Although rare, as documented by several recent reviews, transmission of donor cancer still occurs.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, it has been suggested that emergent retransplantation may be the best treatment option, and several case reports have attested to the validity of this recommendation. 5,6,[10][11][12] Ours is the first case in the literature of donor cancer transmission despite explantation and retransplantation immediately on identification of the donor malignancy, before the identification of tumor transmission in the recipient. Clearly, tumor cells had escaped the confines of the transplanted liver within 1 week after transplantation and gained access to the general circulation.…”

Section: Discussionmentioning

confidence: 99%

Death from donor-transmitted malignancy despite emergency liver retransplantation

Lipshutz

Baxter‐Lowe

Nguyen

et al. 2003

Liver Transplantation

View full text Add to dashboard Cite

Transplantation of organs procured from donors with malignancies identified subsequent to implantation presents a significant dilemma regarding the optimal management strategy to simultaneously minimize the risk for cancer transmission and recipient morbidity. In this report, we present a patient who underwent orthotopic liver transplantation for hepatitis B cirrhosis. The donor had no previous history of cancer. On autopsy, enlarged mediastinal lymph nodes led to the discovery of a 1-cm lung tumor. Histological examination showed pulmonary adenocarcinoma with metastatic mediastinal disease. Despite urgent retransplantation within 7 days, the recipient developed metastatic pulmonary adenocarcinoma diagnosed 11 months after transplantation and died soon thereafter. Analysis of short tandem repeat regions of chromosomal DNA from the recipient, the 2 liver donors, and the posttransplantation tumor corroborates that the first donor was the source of the malignancy. This case of donor-transmitted malignancy underscores the need for vigilance by the procuring surgeon in identifying potential malignancy during organ retrieval and use of a full autopsy on selected donors after organ procurement. (Liver Transpl 2003;9:1102-1107.)

show abstract

Transplant tumor registry: donor related malignancies

Abstract: The United States incidence of donor related tumors is extremely small. The donor related tumor death rate is also extremely small, particularly when compared with waiting-list mortality.

Cited by 218 publications

References 17 publications

Cancer in the Transplant Recipient

Cancer in the Transplant Recipient

The utility of marginal donors in liver transplantation

Death from donor-transmitted malignancy despite emergency liver retransplantation

Contact Info

Product

Resources

About